|
1
|
Calderaro J, Ziol M, Paradis V and
Zucman-Rossi J: Molecular and histological correlations in liver
cancer. J Hepatol. 71:616–630. 2019.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Gomes MA, Priolli DG, Tralhão JG and
Botelho MF: Hepatocellular carcinoma: Epidemiology, biology,
diagnosis, and therapies. Rev Assoc Med Bras (1992). 59:514–524.
2013.PubMed/NCBI View Article : Google Scholar : (In English,
Portuguese).
|
|
3
|
Wu Q and Qin SK: Features and treatment
options of Chinese hepatocellular carcinoma. Chin Clin Oncol.
2(38)2013.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Avila MA, Berasain C, Sangro B and Prieto
J: New therapies for hepatocellular carcinoma. Oncogene.
25:3866–3884. 2006.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Fu J and Wang H: Precision diagnosis and
treatment of liver cancer in China. Cancer Lett. 412:283–288.
2018.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Zhu YJ, Zheng B, Wang HY and Chen L: New
knowledge of the mechanisms of sorafenib resistance in liver
cancer. Acta Pharmacol Sin. 38:614–622. 2017.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Fondevila F, Méndez-Blanco C,
Fernández-Palanca P, González-Gallego J and Mauriz JL: Anti-tumoral
activity of single and combined regorafenib treatments in
preclinical models of liver and gastrointestinal cancers. Exp Mol
Med. 51:1–15. 2019.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Wilhelm SM, Dumas J, Adnane L, Lynch M,
Carter CA, Schütz G, Thierauch KH and Zopf D: Regorafenib (BAY
73-4506): A new oral multikinase inhibitor of angiogenic, stromal
and oncogenic receptor tyrosine kinases with potent preclinical
antitumor activity. Int J Cancer. 129:245–255. 2011.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Chiang CH, Chung JG and Hsu FT:
Regorefenib induces extrinsic/intrinsic apoptosis and inhibits
MAPK/NF-κB-modulated tumor progression in bladder cancer in vitro
and in vivo. Environ Toxicol. 34:679–688. 2019.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Sun H, Feng F, Xie H, Li X, Jiang Q, Chai
Y, Wang Z, Yang R, Li R and Hou J: Quantitative examination of the
inhibitory activation of molecular targeting agents in
hepatocellular carcinoma patient-derived cell invasion via a novel
in vivo tumor model. Animal Model Exp Med. 2:259–268.
2019.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Li S, Wang A, Gu F, Wang Z, Tian C, Qian
Z, Tang L and Gu Y: Novel harmine derivatives for tumor targeted
therapy. Oncotarget. 6:8988–9001. 2015.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Prasad Kushwaha J, Baidya D and Patil S:
Harmine-loaded galactosylated pluronic F68-gelucire 44/14 mixed
micelles for liver targeting. Drug Dev Ind Pharm. 45:1361–1368.
2019.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Zhang L, Zhang F, Zhang W, Chen L, Gao N,
Men Y, Xu X and Jiang Y: Harmine suppresses homologous
recombination repair and inhibits proliferation of hepatoma cells.
Cancer Biol Ther. 16:1585–1592. 2015.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Jalali A, Dabaghian F and Zarshenas MM:
Alkaloids of Peganum harmala: Anticancer biomarkers with
promising outcomes. Curr Pharm Des. 27:185–196. 2021.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Seifert A, Allan LA and Clarke PR: DYRK1A
phosphorylates caspase 9 at an inhibitory site and is potently
inhibited in human cells by harmine. FEBS J. 275:6268–6280.
2008.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Li Y, Zhou D, Xu S, Rao M, Zhang Z, Wu L,
Zhang C and Lin N: DYRK1A suppression restrains Mcl-1 expression
and sensitizes NSCLC cells to Bcl-2 inhibitors. Cancer Biol Med.
17:387–400. 2020.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Li YL, Ding K, Hu X, Wu LW, Zhou DM, Rao
MJ, Lin NM and Zhang C: DYRK1A inhibition suppresses STAT3/EGFR/Met
signalling and sensitizes EGFR wild-type NSCLC cells to AZD9291. J
Cell Mol Med. 23:7427–7437. 2019.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Li YL, Zhang NY, Hu X, Chen JL, Rao MJ, Wu
LW, Li QY, Zhang B, Yan W and Zhang C: Evodiamine induces apoptosis
and promotes hepatocellular carcinoma cell death induced by
vorinostat via downregulating HIF-1α under hypoxia. Biochem Biophys
Res Commun. 498:481–486. 2018.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Vichai V and Kirtikara K: Sulforhodamine B
colorimetric assay for cytotoxicity screening. Nat Protoc.
1:1112–1116. 2006.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Riccardi C and Nicoletti I: Analysis of
apoptosis by propidium iodide staining and flow cytometry. Nat
Protoc. 1:1458–1461. 2006.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Zhang C, Shi J, Mao SY, Xu YS, Zhang D,
Feng LY, Zhang B, Yan YY, Wang SC, Pan JP, et al: Role of p38 MAPK
in enhanced human cancer cells killing by the combination of
aspirin and ABT-737. J Cell Mol Med. 19:408–417. 2015.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Zhang D, Yan B, Yu S, Zhang C, Wang B,
Wang Y, Wang J, Yuan Z, Zhang L and Pan J: Coenzyme Q10 inhibits
the aging of mesenchymal stem cells induced by D-galactose through
Akt/mTOR signaling. Oxid Med Cell Longev.
2015(867293)2015.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Kahraman DC, Kahraman T and Cetin-Atalay
R: Targeting PI3K/Akt/mTOR pathway identifies differential
expression and functional role of IL8 in liver cancer stem cell
enrichment. Mol Cancer Ther. 18:2146–2157. 2019.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Chen W, Yang J, Zhang Y, Cai H, Chen X and
Sun D: Regorafenib reverses HGF-induced sorafenib resistance by
inhibiting epithelial-mesenchymal transition in hepatocellular
carcinoma. FEBS Open Bio. 9:335–347. 2019.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Mirone G, Perna S, Shukla A and Marfe G:
Involvement of notch-1 in resistance to regorafenib in colon cancer
cells. J Cell Physiol. 231:1097–1105. 2016.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Xiang W, Yang CY and Bai L: MCL-1
inhibition in cancer treatment. Onco Targets Ther. 11:7301–7314.
2018.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Wei SH, Dong K, Lin F, Wang X, Li B, Shen
JJ, Zhang Q, Wang R and Zhang HZ: Inducing apoptosis and enhancing
chemosensitivity to gemcitabine via RNA interference targeting
Mcl-1 gene in pancreatic carcinoma cell. Cancer Chemother
Pharmacol. 62:1055–1064. 2008.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Jin L, Hu WL, Jiang CC, Wang JX, Han CC,
Chu P, Zhang LJ, Thorne RF, Wilmott J, Scolyer RA, et al:
MicroRNA-149*, a p53-responsive microRNA, functions as an oncogenic
regulator in human melanoma. Proc Natl Acad Sci USA.
108:15840–15845. 2011.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Noll C, Tlili A, Ripoll C, Mallet L, Paul
JL, Delabar JM and Janel N: Dyrk1a activates antioxidant NQO1
expression through an ERK1/2-Nrf2 dependent mechanism. Mol Genet
Metab. 105:484–488. 2012.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Abekhoukh S, Planque C, Ripoll C, Urbaniak
P, Paul JL, Delabar JM and Janel N: Dyrk1A, a serine/threonine
kinase, is involved in ERK and Akt activation in the brain of
hyperhomocysteinemic mice. Mol Neurobiol. 47:105–116.
2013.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Li L, Wei JR, Song Y, Fang S, Du Y, Li Z,
Zeng TT, Zhu YH, Li Y and Guan XY: TROAP switches DYRK1 activity to
drive hepatocellular carcinoma progression. Cell Death Dis.
12(125)2021.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Yang YM, Kim SY and Seki E: Inflammation
and liver cancer: Molecular mechanisms and therapeutic targets.
Semin Liver Dis. 39:26–42. 2019.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Ringelhan M, Pfister D, O'Connor T,
Pikarsky E and Heikenwalder M: The immunology of hepatocellular
carcinoma. Nat Immunol. 19:222–232. 2018.PubMed/NCBI View Article : Google Scholar
|
|
34
|
He M, Zhang W, Dong Y, Wang L, Fang T,
Tang W, Lv B, Chen G, Yang B, Huang P and Xia J: Pro-inflammation
NF-κB signaling triggers a positive feedback via enhancing
cholesterol accumulation in liver cancer cells. J Exp Clin Cancer
Res. 36(15)2017.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Koike K: Expression of junB is markedly
stimulated by glycyrrhizin in a human hepatoma cell line. Oncol
Rep. 25:609–617. 2011.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Khor B, Gagnon JD, Goel G, Roche MI,
Conway KL, Tran K, Aldrich LN, Sundberg TB, Paterson AM, Mordecai
S, et al: The kinase DYRK1A reciprocally regulates the
differentiation of Th17 and regulatory T cells. Elife.
4(e05920)2015.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Pozo N, Zahonero C, Fernández P, Liñares
JM, Ayuso A, Hagiwara M, Pérez A, Ricoy JR, Hernández-Laín A,
Sepúlveda JM and Sánchez-Gómez P: Inhibition of DYRK1A destabilizes
EGFR and reduces EGFR-dependent glioblastoma growth. J Clin Invest.
123:2475–2487. 2013.PubMed/NCBI View
Article : Google Scholar
|
